Clinical and symptomatological characterization regarding Chagas disease caused by the Trypanosoma cruzi parasite

Neglected diseases are a group of communicable diseases that mainly affect tropical regions of developing countries. Among this group of diseases is Chagas disease, which has been classified among the six most important parasitic diseases in the world, and it is estimated that more than one billion people are at risk in endemic countries. The objective of this study is to review the literature on the symptomatological and clinical characterization of Chagas disease caused by Trypanosoma cruzi. This is an integrative literature review study. For this, we used the following descriptors in the search: Trypanosoma cruzi, epidemiological profile, Chagas disease and clinical aspects (together and separately). In the selection criteria we opted for full articles, in the period 2013 - 2021 (last 9 years), in Portuguese and English. The searches were conducted in the following databases: Scientific Electronic Library Online (Scielo), Pubmed, Latin American and Caribbean Literature on Health Sciences (Lilacs), Google Scholar. The articles were selected first by title, then by abstract, and finally by complete reading. The literature shows that Chagas disease is caused by the protozoan Trypanosoma cruzi, characterized by the presence of a flagellum and kinetoplast. Some of its clinical manifestations include: fever, asthenia, adynamia, myalgia, arthralgia, headache, myocarditis, and hepatosplenomegaly. Therefore, it is important to know all the characteristics of this disease, since it can be considered a public health problem. It is suggested that new studies be carried out with different approaches, in order to elucidate even more specifically the dynamics surrounding this disease.

[1]  J. R. Correia,et al.  Doença de Chagas: aspectos clínicos, epidemiológicos e fisiopatológicos , 2021 .

[2]  Gabriel da Silva Macedo,et al.  Revalidação do painel sorológico empregado na avaliação dos kits de diagnóstico da doença de Chagas , 2020 .

[3]  J. Altcheh,et al.  Adverse Events Associated with Nifurtimox Treatment for Chagas Disease in Children and Adults , 2020, Antimicrobial Agents and Chemotherapy.

[4]  João Paulo Toledo,et al.  Doenças infecciosas e parasitárias no Brasil de 2010 a 2017: aspectos para vigilância em saúde , 2020, Revista panamericana de salud publica = Pan American journal of public health.

[5]  F. Chappuis,et al.  Tolerance to nifurtimox and benznidazole in adult patients with chronic Chagas’ disease , 2019, The Journal of antimicrobial chemotherapy.

[6]  R. Novaes,et al.  An evaluation of benznidazole as a Chagas disease therapeutic , 2019, Expert opinion on pharmacotherapy.

[7]  C. Almeida,et al.  Morphobiological, morphometric and ultrastructural characterization of sylvatic Trypanosoma cruzi isolates from Rio de Janeiro state, Brazil. , 2019, Brazilian journal of biology = Revista brasleira de biologia.

[8]  W. Monteiro,et al.  Oral Transmission of Trypanosoma cruzi, Brazilian Amazon , 2019, Emerging infectious diseases.

[9]  Andréa Bessa Teixeira,et al.  Métodos de diagnóstico para a doença de Chagas: uma atualização , 2019 .

[10]  A. Ribeiro,et al.  Beneficial effects of benznidazole in Chagas disease: NIH SaMi-Trop cohort study , 2018, PLoS neglected tropical diseases.

[11]  E. Kransdorf,et al.  Diagnosis and Management of Chagas Cardiomyopathy in the United States , 2018, Current Cardiology Reports.

[12]  A. L. R. Roque,et al.  Trypanosoma cruzi transmission in the wild and its most important reservoir hosts in Brazil , 2018, Parasites & Vectors.

[13]  Eduardo Arrais Rocha,et al.  Trypanosoma cruzi seroprevalence among solid organ donors in Ceará State, Brazil. , 2018, Revista da Sociedade Brasileira de Medicina Tropical.

[14]  G. Buck,et al.  Trypanosoma rangeli is phylogenetically closer to Old World trypanosomes than to Trypanosoma cruzi. , 2018, International journal for parasitology.

[15]  E. Dumonteil,et al.  Detailed ecological associations of triatomines revealed by metabarcoding and next-generation sequencing: implications for triatomine behavior and Trypanosoma cruzi transmission cycles , 2018, Scientific Reports.

[16]  C. Bezerra,et al.  Insect vectors of Chagas disease (Trypanosoma cruzi) in Northeastern Brazil. , 2018, Revista da Sociedade Brasileira de Medicina Tropical.

[17]  Jadher Percio,et al.  Investigação de surto de doença de Chagas aguda na região extra-amazônica, Rio Grande do Norte, Brasil, 2016 , 2018 .

[18]  B. Zingales Trypanosoma cruzi genetic diversity: Something new for something known about Chagas disease manifestations, serodiagnosis and drug sensitivity. , 2017, Acta tropica.

[19]  M. Cowie,et al.  Heart failure: classification and pathophysiology , 2010, Medicine.

[20]  Rejane Seila da Silva Castro Construção e validação de um manual para diagnóstico de doença de Chagas , 2018 .

[21]  R. Tarleton,et al.  Spontaneous dormancy protects Trypanosoma cruzi during extended drug exposure , 2017, bioRxiv.

[22]  D. D. Souza,et al.  Aspectos epidemiológicos e clínicos da Doença de Chagas aguda no Brasil e na américa Latina , 2016 .